Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older ...

The stock's fall snapped a two-day winning streak.

January 3 - The Toronto Maple Leafs signed defenseman Philippe Myers to a two-year, $1.7 million contract extension Friday. Myers, 27, has recorded two assists in 11 games in his first season with ...

Looking at the universe of stocks we cover at Dividend Channel, on 1/3/25, Bristol Myers Squibb Co. (Symbol: BMY), Globe Life Inc (Symbol: GL), and American Express Co. (Symbol: AXP) will all ...

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in the U.S., the agency has cleared an under-the-skin version of the ...

Inigo Calderon's first home game in charge as Bristol Rovers manager ended in disappointment as in-form Leyton Orient ran out 3-2 winners at the Memorial Stadium. It left Rovers hovering just ...

If you’re on the fence about investing in Bristol-Myers Squibb Company or Zoetis Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your ...

Financial giants have made a conspicuous bullish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb BMY revealed 10 unusual trades. Delving into the details ...

Pharmaceutical company Bristol-Myers Squibb (BMY) has received approval from the Food and Drug Administration (FDA) for an injectible version of Opdivo. This is big news for BMY as Opdivo is its ...

Bristol-Myers Squibb stock has rebounded strongly in 2024, driven by key drug approvals and positive financial performance, with shares rising from ~$40 to ~$60. The approval of Opdivo Qvantig ...